Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00700635 · ClinicalTrials.gov registry record · Phase 2
Dose Comparison Study of Menactra® in US Children
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 333
- Enrollment target
NCT00700635 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 333 participants.
The verdict
NCT00700635, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 333 participants
- Enrollment target
Study Summary
To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.
Interventions
- BIOLOGICAL Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00700635
The ClinicalTrials.gov registry entry for NCT00700635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate is the first listed.
NCT00700635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00700635 about?
NCT00700635 is a clinical study titled "Dose Comparison Study of Menactra® in US Children". To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.
What is the current status of trial NCT00700635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 333 participants. The study started on 2008-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00700635?
The interventions under investigation include: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00700635?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.